NASDAQ : ATC

GraniteShares Autocallable COIN ETF — News

$21.3274 USD

-$0.29 (-1.35%)

Volume
73
Average Volume
748
Market Capitalization
$829.36K
P/E Ratio
517.51
Dividend Yield
6.16%
Price Target
Year High
$25.11
Year Low
$19.96
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.72
Source Headline
ATERRA Reports Totora Cu/Au Project Drilling Returns 284 m Grading 0.64% CuEq Including 180 m at 0.71% CuEq

Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - ATERRA Metals Inc. (CSE: ATC) (OTCQB: CSSCF) ("ATERRA") is pleased to report Phase I drill assay results from its Totora Cu/Au Project located in the Dos Amigo Mining District, 15 kilometres south of Tintina Mines' Domekyo Sulfurous development project. Highlights AFROD01 returned 284 metres grading 0.64% copper equivalent ("CuEq") from surface at the Frontera Cu/Au Deposit (0.41% Cu and 0.27 grams per tonne ("g/t") gold)  including 180 metres grading 0.71% CuEq (0.48% Cu and 0.28 g/t Au) including 70 metres grading 0.82% CuEq (0.56% Cu and 0.32 g/t Au) ATOD01 returned 194 metres grading 0.41% CuEq (0.35% Cu and 0.11 g/t Au) collared on the Totora Porphyry Drilling confirmed the presence of significant copper and gold mineralization at both the Frontera Deposit and nearby Totora Cu/Au Porphyry highlighting the potential of the Totora Cu/Au Project Table 1 - Highlights of Totora Phase I Drill Assay Results Drill Hole From To Interval CuEq Cu Au Target (metres) (%) (%) (g/t) AFROD01 0.0 284.0 284.0 0.64 0.41 0.27 Frontera incl.

newsfilecorp.com - 2026-07-16 07:30:00

GraniteShares Announces Monthly Distributions for its Autocallable ETFs: ANV, TLA, MSR, ATC, PLA, AHD, SCA and MRA

New York, July 02, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the monthly distributions for its GraniteShares Autocallable ETFs: ANV, TLA, MSR, ATC, PLA, AHD, SCA and MRA as shown in the table below.

globenewswire.com - 2026-07-02 12:46:00

CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.

businesswire.com - 2026-06-18 07:05:00

Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026

Schlieren / Zurich, Switzerland, 18 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces the presentation of data from its Phase II clinical trial of potravitug at the American Transplant Congress (ATC) 2026, taking place from 20-24 June in Boston, USA.

globenewswire.com - 2026-06-18 07:00:00

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transp.

businesswire.com - 2026-06-18 06:00:00

Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026

FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that collaborators will present new data on the predictive performance of its Tutivia™ test at the American Transplant Congress (ATC) Annual Meeting, taking place June 20–24, 2026 in Boston. The abstracts are available via the planner on the ATC website. The two poster presentations, delivered by leading transplant clinicians, describe the ability of Tutiv.

businesswire.com - 2026-06-17 08:00:00

World Wide Technology Launches ‘Defending at the Speed of AI' Initiative with Horizon3.ai, Empirical Security, Infoblox, and Cognition

ST. LOUIS--(BUSINESS WIRE)--World Wide Technology (WWT), a global technology solutions provider, today announced the launch of “Defending at the Speed of AI,” a global cybersecurity initiative WWT developed in collaboration with Horizon3.ai, Empirical Security, Infoblox, and Cognition. The integrated program, available in WWT's Advanced Technology Center (ATC) and Cyber Range, operates at machine speed to address a critical gap in modern security infrastructure: the accelerating pace of AI-powe.

businesswire.com - 2026-06-16 10:00:00

ATERRA Announces Completion of Totora Phase I Drill Program

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - ATERRA Metals Inc. (CSE: ATC) (OTCQB: CSSCF) ("ATERRA") is pleased to report that the Totora Cu-Au Project Phase I drill program has been finished with a total of 2,745.6 metres of drilling completed: 1,571.5 metres of reverse circulation and 1,174.1 metres of diamond drilling (Table 1). The Totora Cu-Au Project is located within the Dos Amigos Mining District, 60 kilometres south of the City of Vallenar, Region III, Chile, and 15 kilometres south of Tintina Mines' Domeyko Sulfuros Project (Figure 1).

newsfilecorp.com - 2026-06-08 09:06:00

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News

gurufocus.com - 2026-05-25 23:00:00

Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. The presentation will include detailed 12-month results from the ConfIdeS trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results.

prnewswire.com - 2026-05-25 22:52:00

Get ATC Insider Trade Alerts

ATC Price Target Summary

Last Month

0 analysts

Last Quarter

0 analysts

Last Year

0 analysts

All Time

0 analysts

ATC Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade